特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
941253

アジア太平洋地域のバイオプロセシング施設(2020年)

Asia-Pacific Bioprocessing Facilities Report 2020

出版日: | 発行: IMAPAC PTE. LTD | ページ情報: 英文 300 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.89円
アジア太平洋地域のバイオプロセシング施設(2020年)
出版日: 2020年04月20日
発行: IMAPAC PTE. LTD
ページ情報: 英文 300 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートはアジア太平洋地域のバイオプロセシング施設について調査しており、規制や承認、施設規模、財務的洞察、地域別のバイオプロセシング施設のデータ等の情報を提供しています。

目次

セクション

  • 序文
  • 調査範囲とデータの範囲
  • IMAPACの調査手法

第2章 大中華圏のバイオプロセシング施設

  • Henlius Pharma
  • Innovent Biologics
  • Pfizer
  • Tonhua Dongbao
  • AlphaMab
  • Akeso Pharmaceuticals
  • Hanmi Pharma
  • Sinovac
  • BeiGene
  • Junshi Biosciences
  • Tot Biopharma
  • Hualan Biological Engineering

第3章 韓国と日本のバイオプロセシング施設

  • Samsung Bioepis
  • Astellas
  • Celltrion
  • 中外製薬株式会社
  • Hanmi Pharma
  • 協和キリン株式会社
  • Aprogen Biologiccs
  • 第一三共株式会社

第4章 インドとオーストラリアのバイオプロセシング施設

  • Aurobindo
  • CSL Bering
  • Serum Institute of India
  • CSIRO
  • Enzene Biosciences
  • Stelis Biopharma

第5章 東南アジアのバイオプロセシング施設

  • Abbvie
  • GSK
  • AJ Biologics
  • Amgen
  • Novartis Thailand
  • Baxter
  • 武田薬品工業株式会社
  • Siam Biosciences

第6章 地域ごとのデータと製造施設の分析(対象地域:中国、台湾、日本、韓国、インド、オーストラリア、東南アジア)

  • 製造される製品:ワクチン・細胞療法・組換えタンパク質およびモノクローナル抗体・その他
  • 収納技術・バイオプロセス
  • プラント容量
  • パイプラインのプロジェクト
  • バイオ製造投資
  • 規制・承認
  • 施設規模、設計
  • 財務的洞察
  • PESTEL分析

第7章 その他

  • 参考文献
  • 免責事項
  • 当社に関して
  • その他のレポート
図表

List Of Tables

Summary Of Manufacturing Facilities

  • Table 1: List of Top 50 Manufacturing Facilities Across Asia Pacific Covered In The Report
  • Table 2: Plant Capacity
  • Table 3: Projects Completed Thus far
  • Table 4: Financial Insights

Region Wise Analysis

China, Taiwan, India Korea, Japan, Australia, Sea

  • Table 5: Investment of Manufacturing Facilities in Greater China
  • Table 6: Investment of Manufacturing Facilities in SEA
  • Table 7: Investment of Manufacturing Facilities in Korea
  • Table 8: Bioprocessing tools, technologies and solutions in Greater China
  • Table 9: Bioprocessing tools, technologies and solutions in Japan
  • Table 10: Bioprocessing tools, technologies and solutions in Korea
  • Table 11: Facility Size and Design in Greater China
  • Table 12: Facility Size and Design in Korea
  • Table 13: Facility Size and Design in Japan
  • Table 14: Checklist for facility of the future in Greater China
  • Table 15: Checklist for facility of the future in Korea
  • Table 16: Checklist for facility of the future in Japan
  • Table 17: Product-Wise segregation for facilities in Greater China
  • Table 18: Product-Wise segregation for facilities in Korea
  • Table 19: Product-Wise segregation for facilities in Japan

List Of Figures

Regions Covered In Asia

  • Figure 1: Top 50 Bioprocessing Manufacturing Facilities from all the Asian Regions

China

  • Figure 2: Investment of Manufacturing Facility
  • Figure 3: Year of Operation
  • Figure 4: Distribution of Single- Use Bioreactors over the years
  • Figure 5: Size of the Facility
  • Figure 6: Manufacturing projects in Pipeline
  • Figure 7: Team Distribution (Manufacturing: Non-Manufacturing)

Taiwan

  • Figure 8: Investment of Manufacturing Facility
  • Figure 9: Year of Operation
  • Figure 10: Distribution of Single- Use Bioreactors over the years
  • Figure 11: Size of the Facility
  • Figure 12: Manufacturing projects in Pipeline
  • Figure 13: Team Distribution (Manufacturing: Non-Manufacturing)

Korea & Japan

  • Figure 14: Investment of Manufacturing Facility
  • Figure 15: Year of Operation
  • Figure 16: Distribution of Single- Use Bioreactors over the years
  • Figure 17: Size of the Facility
  • Figure 18: Manufacturing projects in Pipeline
  • Figure 19: Team Distribution (Manufacturing: Non-Manufacturing)

Japan

  • Figure 20: Investment of Manufacturing Facility
  • Figure 21: Year of Operation
  • Figure 22: Distribution of Single- Use Bioreactors over the years
  • Figure 23: Size of the Facility
  • Figure 24: Manufacturing projects in Pipeline
  • Figure 25: Team Distribution (Manufacturing: Non-Manufacturing)

India

  • Figure 26: Investment of Manufacturing Facility
  • Figure 27: Year of Operation
  • Figure 28: Distribution of Single- Use Bioreactors over the years
  • Figure 29: Size of the Facility
  • Figure 30: Manufacturing projects in Pipeline
  • Figure 31: Team Distribution (Manufacturing: Non-Manufacturing)
目次

The Biologics industry is evolving at an unprecedented rate by demanding for new and improved technologies to reduce cost and increase efficiency. The world is seeing an increase in Biopharma facilities, especially in Asia to meet the growing demands of biologic drugs. Yet, the number one factor reported to cause capacity constraints at bioprocessing facilities in the near future is facility constraints.

Hence, IMAPAC has put together a comprehensive report on 65+ Bioprocessing facilities in the past ten years that have been constructed in the Asia- Pacific region including countries such as China, India, Korea, Japan, SEA, Australia. This report will provide detailed analysis from their manufacturing capabilities, Process Technologies to key details on their Facility Construction Design. We will be providing information straight from our interaction with top players in the industry and key management of companies, on how their facilities provide them with the flexibility to expand their manufacturing capabilities while cutting cost.

Are you also looking to expand your operations to meet the growing global demands? If you would like to learn from the successful players in the industry and not repeat the same mistakes as some of your competitors, check out the full report now.

Table of Contents

Section 1

  • Preface
  • Report Scope & Data Coverage
  • IMAPAC's Research Methodology

Section 2: Bioprocessing Facilities in Greater China

  • Henlius Pharma
  • Innovent Biologics
  • Pfizer
  • Tonhua Dongbao
  • AlphaMab
  • Akeso Pharmaceuticals
  • Hanmi Pharma
  • Sinovac
  • BeiGene
  • Junshi Biosciences
  • Tot Biopharma
  • Hualan Biological Engineering

Section 3: Bioprocessing Facilities In Korea And Japan

  • Samsung Bioepis
  • Astellas
  • Celltrion
  • Chugai
  • Hanmi Pharma
  • Kyowa Hakko Kirin
  • Aprogen Biologiccs
  • Daiichi Sankyo

Section 4: Bioprocessing Facilities In India And Australia

  • Aurobindo
  • CSL Bering
  • Serum Institute of India
  • CSIRO
  • Enzene Biosciences
  • Stelis Biopharma

Section 5: Bioprocessing Facilities In South-East-Asia

  • Abbvie
  • GSK
  • AJ Biologics
  • Amgen
  • Novartis Thailand
  • Baxter
  • Takeda
  • Siam Biosciences

Section 6: Region-Wise Data & Analysis Of Manufacturing Facility {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}

  • Products Manufactured: Vaccines - Cell Therapy - Recombinant Proteins & Mabs - Others
  • Technologies Housed and Bioprocessing Processes
  • Plant Capacity
  • Projects In Pipeline
  • Biomanufacturing Investment
  • Regulatory Approvals
  • Facility Size, Design
  • Financial Insights
  • Pestel Analysis

Section 7: Our Other Reports

  • Bibiliography
  • Disclaimer
  • About Us
  • Our Other Reports
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.